What Happens Before the First Dose? 5 Steps That Shape Lung Cancer Treatment

The first dose of lung cancer therapy marks a visible milestone, but decisions made beforehand determine how a patient reaches it. A pathology report establishes the diagnosis. Staging defines the extent of disease. For patients with non–small cell lung cancer (NSCLC), biomarker findings can change which treatment is appropriate.^1,2

As Lung Cancer Awareness Month begins, the period before treatment deserves attention. It is also an opportunity for pharmacists to help translate a treatment recommendation into a plan patients can follow. These 5 steps explain what happens before the first dose, and where pharmacy involvement matters.

1. Confirm Exactly What Is Being Treated

Lung cancer treatment begins with a tissue diagnosis, not an imaging finding alone. Distinguishing NSCLC from small cell lung cancer is essential because their treatment approaches differ. Within NSCLC, histologic classification further informs treatment selection. The National Cancer Institute emphasizes review of pathological material by an experienced lung cancer pathologist before treatment begins.¹

The biopsy also supplies material for additional testing. An inadequate specimen can leave clinically important questions unanswered, including whether the tumor carries a treatment-relevant biomarker.² Pharmacists who are reviewing a proposed regimen should understand the documented diagnosis and flag discrepancies between the pathology and treatment plan for clarification.

2. Establish Stage Before Mapping the Treatment Sequence

Stage describes how far the cancer has spread and helps determine the role of surgery, radiation, and systemic treatment. Depending on the clinical situation, staging may involve PET imaging, brain imaging, or sampling of lymph nodes. The patient’s overall health also influences the treatment recommendation.¹

For pharmacists, this context explains why the same medication may appear at different points in care. Systemic treatment can precede surgery, follow it, or serve as the main treatment for advanced disease.^1,3 Understanding the intended sequence helps pharmacists verify when therapy should start and explain its purpose. Patients should know whether a medication is being used to reduce recurrence risk or to control cancer that has spread.

3. Complete the Biomarker Picture

In NSCLC, treatment selection can depend on the tumor’s molecular characteristics. Testing can identify alterations such as EGFR mutations that match an available targeted therapy. Protein biomarkers, including PD-L1, also inform treatment decisions. These tests answer different questions; one result does not replace the others.^1,2

Biomarker testing may use tumor tissue or, in selected circumstances, a blood-based liquid biopsy. Testing is not always informative: a specimen may contain insufficient material, or testing may fail to identify a treatment-matching alteration.²

Pharmacists can help identify whether relevant results remain outstanding before a proposed regimen begins. When disease requires urgent treatment, the oncology team must weigh the patient’s clinical condition against the value of additional information. The practical question is whether pending findings could change the planned therapy.^1,2

4. Check Whether the Patient Is Ready for the Regimen

Selecting an appropriate drug does not complete the safety assessment. Treatment decisions also account for comorbidities and the patient’s ability to tolerate therapy. Chemotherapy and targeted therapies have different safety profiles and adverse effects, so preparation should reflect the actual regimen.^1,3,4

A pharmacist’s pretreatment review should reconcile prescription medications with OTC products and supplements, then check for regimen-specific interactions. Baseline laboratory results and any additional monitoring requirements should be reviewed against the selected treatment’s prescribing information.

Education belongs here, too. For an oral therapy, patients need clear instructions about administration and missed doses. For any regimen, they should understand which symptoms require prompt contact and how to reach the care team. Supportive medications should be explained before patients need them.

5. Make Sure the Plan Can Reach the Patient

The final barrier may be practical. Cancer care can create substantial expenses even for insured patients, and costs extend beyond the medication itself. Travel and missed work can affect whether a treatment plan is manageable.⁵

Before treatment starts, pharmacy teams can help clarify coverage requirements and connect patients with financial assistance resources. For oral treatment, confirming the dispensing pharmacy and expected delivery helps establish a realistic start date. Patients receiving infusions may need help coordinating transportation.

These conversations should occur early enough to address problems. A treatment plan becomes actionable when the patient can obtain the medication, understands how to use it, and knows where to turn when difficulties arise.

REFERENCES

1. PDQ Adult Treatment Editorial Board. Non-Small Cell Lung Cancer Treatment (PDQ®): Health Professional Version. 2025 May 7. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002. Accessed October 30, 2026. https://www.ncbi.nlm.nih.gov/books/NBK65865/

2. Biomarker testing for cancer treatment. National Cancer Institute. Accessed October 30, 2026. biomarker-testing-cancer-treatment

3. Chemotherapy to treat cancer. National Cancer Institute. Accessed October 30, 2026. chemotherapy

4. Targeted therapy to treat cancer. National Cancer Institute. Updated October 21, 2024. Accessed October 30, 2026. https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies

5. Managing cancer costs and medical information. National Cancer Institute. Updated May 31, 2022. Accessed October 30, 2026. https://www.cancer.gov/about-cancer/managing-care/track-care-costs